Biological factors, tumor growth kinetics, and survival after metastasectomy for pulmonary melanoma.

PubWeight™: 0.84‹?›

🔗 View Article (PMC 2752490)

Published in Ann Surg Oncol on July 15, 2009


Jonathan H Lee1, Seza A Gulec, Ainura Kyshtoobayeva, Myung-Shin Sim, Donald L Morton

Author Affiliations

1: Division of Surgical Oncology, John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, CA, USA.

Articles cited by this

Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74

On the origin of cancer cells. Science (1956) 49.55

Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol (2001) 10.20

Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol (2001) 9.68

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol (1996) 9.68

Cancer statistics, 1997. CA Cancer J Clin (1997) 5.22

Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg (1995) 4.37

High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am (2000) 4.19

Caspase-3-generated fragment of gelsolin: effector of morphological change in apoptosis. Science (1997) 4.19

A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol (1983) 3.80

A multifactorial analysis of melanoma: III. Prognostic factors in melanoma patients with lymph node metastases (stage II). Ann Surg (1981) 2.09

Improved survival with pulmonary metastasectomy: an analysis of 1720 patients with pulmonary metastatic melanoma. J Thorac Cardiovasc Surg (2007) 1.96

Tumor doubling time: a selection factor for pulmonary resection of metastatic melanoma. J Surg Oncol (1998) 1.71

The glycolytic phenotype in carcinogenesis and tumor invasion: insights through mathematical models. Cancer Res (2003) 1.67

Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer. J Nucl Med (1997) 1.58

Contemporary surgical treatment of advanced-stage melanoma. Arch Surg (2004) 1.52

Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol (2002) 1.38

Metastasectomy for recurrent stage IV melanoma. J Surg Oncol (1999) 1.18

Intratumoral distribution of tritiated-FDG in breast carcinoma: correlation between Glut-1 expression and FDG uptake. J Nucl Med (1996) 1.15

Resection and adjuvant immunotherapy for melanoma metastatic to the lung and thorax. J Thorac Cardiovasc Surg (1995) 1.13

18F-FDG PET scanning correlates with tissue markers of poor prognosis and predicts mortality for patients after liver resection for colorectal metastases. J Nucl Med (2007) 1.12

Using positron emission tomography with [(18)F]FDG to predict tumor behavior in experimental colorectal cancer. Neoplasia (2001) 1.11

Application of quantitative models from population biology and evolutionary game theory to tumor therapeutic strategies. Mol Cancer Ther (2003) 1.08

Surgical resection as the treatment of choice for melanoma metastatic to the lung. Chest Surg Clin N Am (1998) 0.92

MIB-1, Ki67, and PCNA scores and DNA flow cytometry in intermediate grade malignant lymphomas. J Clin Pathol (1994) 0.87

Surgical resection and adjunctive immunotherapy for selected patients with multiple pulmonary metastases. Ann Surg (1973) 0.86

Surgical resection for metastatic melanoma to the lung. Arch Surg (1988) 0.85

Assessment of cell proliferation by Ki-67 staining and flow cytometry in fine needle aspirates (FNAs) of reactive lymphadenitis and non-Hodgkin's lymphomas. Cytopathology (1999) 0.81

Tumor doubling time and survival J Surg Oncol (1999) 0.78

A surgical perspective on positron emission tomography. J Surg Oncol (2007) 0.77

Articles by these authors

Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08

A landscape of driver mutations in melanoma. Cell (2012) 12.61

Sentinel node biopsy and standard of care for melanoma. J Am Acad Dermatol (2009) 4.32

Impact of micrometastases in the sentinel node of patients with invasive breast cancer. J Clin Oncol (2009) 3.36

Activation of CCR9/CCL25 in cutaneous melanoma mediates preferential metastasis to the small intestine. Clin Cancer Res (2008) 3.24

The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I). Ann Surg Oncol (2010) 3.02

Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma. J Clin Oncol (2008) 2.53

Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol (2010) 2.30

Prognostic impact of micrometastases in colon cancer: interim results of a prospective multicenter trial. Ann Surg (2007) 2.28

An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin (2004) 2.18

Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin Cancer Res (2004) 2.05

Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study. Ann Surg Oncol (2006) 2.00

Epigenome-wide DNA methylation landscape of melanoma progression to brain metastasis reveals aberrations on homeobox D cluster associated with prognosis. Hum Mol Genet (2013) 1.95

Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). Ann Surg Oncol (2012) 1.92

Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach. J Nucl Med (2003) 1.88

Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene (2004) 1.81

Prolonged survival after complete resection of metastases from intraocular melanoma. Cancer (2004) 1.78

Prediction of disease outcome in melanoma patients by molecular analysis of paraffin-embedded sentinel lymph nodes. J Clin Oncol (2003) 1.78

Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol (2011) 1.78

CpG island methylator phenotype predicts progression of malignant melanoma. Clin Cancer Res (2009) 1.77

FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer. Cancer Res (2010) 1.73

Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patients. Clin Cancer Res (2006) 1.72

BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci U S A (2013) 1.72

Preoperative localization and radioguided parathyroid surgery. J Nucl Med (2003) 1.68

Prognostic implications of thick (>or=4-mm) melanoma in the era of intraoperative lymphatic mapping and sentinel lymphadenectomy. Ann Surg Oncol (2002) 1.65

Downregulation of microRNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma. Epigenetics (2011) 1.55

Staging of regional lymph nodes in melanoma: a case for including nonsentinel lymph node positivity in the American Joint Committee on Cancer staging system. JAMA Surg (2013) 1.52

Contemporary surgical treatment of advanced-stage melanoma. Arch Surg (2004) 1.52

Prognostic significance of molecular upstaging of paraffin-embedded sentinel lymph nodes in melanoma patients. J Clin Oncol (2004) 1.50

A collagen-remodeling gene signature regulated by TGF-β signaling is associated with metastasis and poor survival in serous ovarian cancer. Clin Cancer Res (2013) 1.46

Peripheral blood CD4+ T-cell response before postoperative active immunotherapy correlates with clinical outcome in metastatic melanoma. Ann Surg Oncol (2004) 1.44

Serum anti-ganglioside IgM antibodies in soft tissue sarcoma: clinical prognostic implications. Cancer J (2002) 1.43

Systemic irinotecan and regional floxuridine after hepatic cytoreduction in 185 patients with unresectable colorectal cancer metastases. Ann Surg Oncol (2002) 1.42

Preoperative imaging of pulmonary metastases in patients with melanoma: implications for minimally invasive techniques. Arch Surg (2012) 1.41

Correlation of dynamic contrast enhancement MRI parameters with microvessel density and VEGF for assessment of angiogenesis in breast cancer. J Magn Reson Imaging (2003) 1.40

Serum TA90 immune complex assay can predict outcome after resection of thick (> or =4 mm) primary melanoma and sentinel lymphadenectomy. Ann Surg Oncol (2002) 1.39

Fixation time does not affect the expression of estrogen receptor. Am J Clin Pathol (2010) 1.39

Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol (2002) 1.38

New TNM melanoma staging system: linking biology and natural history to clinical outcomes. Semin Surg Oncol (2003) 1.34

Prediction of metastatic melanoma in nonsentinel nodes and clinical outcome based on the primary melanoma and the sentinel node. Mod Pathol (2004) 1.32

Authors' response to a letter to the editor re: Sentinel node biopsy for early-stage melanoma. Ann Surg (2007) 1.32

Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome. Ann Surg (2006) 1.31

AJCC Cancer Staging Manual 7th edition criteria for colon cancer: do the complex modifications improve prognostic assessment? J Am Coll Surg (2013) 1.31

Does metastasectomy improve survival in patients with Stage IV melanoma? A cancer registry analysis of outcomes. J Surg Oncol (2011) 1.29

Prospective multicenter trial of staging adequacy in colon cancer: preliminary results. Arch Surg (2006) 1.28

Practice patterns and outcomes for anorectal melanoma in the USA, reviewing three decades of treatment: is more extensive surgical resection beneficial in all patients? Ann Surg Oncol (2009) 1.25

Expression of differentiation melanoma-associated antigen genes is associated with favorable disease outcome in advanced-stage melanomas. Cancer Res (2003) 1.24

2009 EANM parathyroid guidelines. Eur J Nucl Med Mol Imaging (2009) 1.24

Endogenous immune response to gangliosides in patients with confined prostate cancer. Int J Cancer (2005) 1.23

Activation of Toll-like receptors 2, 3, and 4 on human melanoma cells induces inflammatory factors. Mol Cancer Ther (2008) 1.23

Age-related lymphatic dysfunction in melanoma patients. Ann Surg Oncol (2009) 1.22

The role of fluorine-18 deoxyglucose positron emission tomography in the management of patients with metastatic melanoma: impact on surgical decision making. Clin Nucl Med (2003) 1.21

Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors. Breast Cancer Res (2008) 1.20

Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma. J Clin Oncol (2004) 1.20

Isolated tumor cells in the sentinel node affect long-term prognosis of patients with melanoma. Ann Surg Oncol (2007) 1.19

Improved survival for stage IV melanoma from an unknown primary site. J Clin Oncol (2009) 1.18

Effect of lymphatic mapping on the new tumor-node-metastasis classification for colorectal cancer. J Clin Oncol (2003) 1.18

Late recurrence in melanoma: clinical implications of lost dormancy. J Am Coll Surg (2013) 1.18

Estrogen receptor-alpha methylation predicts melanoma progression. Cancer Res (2006) 1.18

Effect of granulocyte/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccine. Clin Cancer Res (2009) 1.17

Comparison of patient characteristics and outcomes of contralateral prophylactic mastectomy and unilateral total mastectomy in breast cancer patients. Ann Surg Oncol (2012) 1.15

Melanoma recurrence patterns after negative sentinel lymphadenectomy. Arch Surg (2005) 1.15

Glycoimmunomics of human cancer: current concepts and future perspectives. Future Oncol (2007) 1.14

Sentinel lymphadenectomy does not increase the incidence of in-transit metastases in primary melanoma. J Clin Oncol (2005) 1.12

Regulation of RUNX3 tumor suppressor gene expression in cutaneous melanoma. Clin Cancer Res (2009) 1.11

Quantitative analysis of melanoma-induced cytokine-mediated immunosuppression in melanoma sentinel nodes. Clin Cancer Res (2005) 1.11

Immune responses in the draining lymph nodes against cancer: implications for immunotherapy. Cancer Metastasis Rev (2006) 1.11

Importance of sentinel lymph node biopsy in patients with thin melanoma. Arch Surg (2008) 1.10

AIM1 and LINE-1 epigenetic aberrations in tumor and serum relate to melanoma progression and disease outcome. J Invest Dermatol (2012) 1.09

Human high molecular weight-melanoma-associated antigen: utility for detection of metastatic melanoma in sentinel lymph nodes. Clin Cancer Res (2008) 1.09

mRNA expression and BRAF mutation in circulating melanoma cells isolated from peripheral blood with high molecular weight melanoma-associated antigen-specific monoclonal antibody beads. Clin Chem (2009) 1.07

B7-H3 associated with tumor progression and epigenetic regulatory activity in cutaneous melanoma. J Invest Dermatol (2013) 1.07

Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial. Cancer (2012) 1.05

Surgery for distant melanoma metastasis. Cancer J (2012) 1.03

Survivin expression by metastatic melanoma predicts poor disease outcome in patients receiving adjuvant polyvalent vaccine. Int J Cancer (2005) 1.03

Beta-catenin regulates the gene of MMP-26, a novel metalloproteinase expressed both in carcinomas and normal epithelial cells. Int J Biochem Cell Biol (2004) 1.02

Association between circulating tumor cells and prognosis in patients with stage III melanoma with sentinel lymph node metastasis in a phase III international multicenter trial. J Clin Oncol (2012) 1.01

Vaccine therapy for melanoma: current status and future directions. Vaccine (2007) 1.00

Allelic imbalance of 12q22-23 associated with APAF-1 locus correlates with poor disease outcome in cutaneous melanoma. Cancer Res (2004) 1.00

Sentinel node biopsy in melanoma: technical considerations of the procedure as performed at the John Wayne Cancer Institute. J Surg Oncol (2010) 1.00

Molecular characterization of inflammatory genes in sentinel and nonsentinel nodes in melanoma. Clin Cancer Res (2007) 0.99

The role of sentinel lymph node biopsy in the management of melanoma. Adv Surg (2007) 0.98

Phase I pilot clinical trial of human IgM monoclonal antibody to ganglioside GM3 in patients with metastatic melanoma. Cancer Immunol Immunother (2003) 0.98

Combined intralesional Bacille Calmette-Guérin (BCG) and topical imiquimod for in-transit melanoma. J Immunother (2012) 0.98

Monocyte-derived IL-10 expression predicts prognosis of stage IV melanoma patients. J Immunother (2007) 0.98

In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer. Gynecol Oncol (2004) 0.98

Solitary dermal melanoma: beginning or end of the metastatic process? Ann Surg Oncol (2009) 0.97

Tumor-microenvironment interactions: the fucose-generating FX enzyme controls adhesive properties of colorectal cancer cells. Cancer Res (2004) 0.96

A 21-year analysis of stage I gallbladder carcinoma: is cholecystectomy alone adequate? HPB (Oxford) (2012) 0.96

Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine. Semin Cancer Biol (2003) 0.95

Natural history of melanoma in 773 patients with tumor-negative sentinel lymph nodes. Ann Surg Oncol (2007) 0.95

Enhanced humoral immune response correlates with improved disease-free and overall survival in American Joint Committee on Cancer stage II melanoma patients receiving adjuvant polyvalent vaccine. J Clin Oncol (2002) 0.94

Brain metastasis is predetermined in early stages of cutaneous melanoma by CD44v6 expression through epigenetic regulation of the spliceosome. Pigment Cell Melanoma Res (2014) 0.93

Role of sentinel lymphadenectomy in thin invasive cutaneous melanomas. J Clin Oncol (2003) 0.93

Molecular tumor markers in the blood: early prediction of disease outcome in melanoma patients treated with a melanoma vaccine. J Clin Oncol (2003) 0.92

The role of lymphatic mapping and sentinel node biopsy in the management of atypical and anomalous melanocytic lesions. J Cutan Pathol (2010) 0.92

Age as a predictor of sentinel node metastasis among patients with localized melanoma: an inverse correlation of melanoma mortality and incidence of sentinel node metastasis among young and old patients. Ann Surg Oncol (2014) 0.91